Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors-Reference-Cited by-同舟云学术

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

Published:2009-05-27 Issue:5 Volume:4 Page:e5717
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Jaiswal Bijay S.,Janakiraman Vasantharajan,Kljavin Noelyn M.,Eastham-Anderson Jeffrey,Cupp James E.,Liang Yuxin,Davis David P.,Hoeflich Klaus P.,Seshagiri Somasekar

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference35 articles.

1. Hyperactive Ras in developmental disorders and cancer.;S Schubbert;Nat Rev Cancer,2007

2. Targeting oncogenic Ras.;E Diaz-Flores;Genes Dev,2007

3. Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders.;CP Kratz;Cell Cycle,2006

4. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?;GA Repasky;Trends Cell Biol,2004

5. Tumour cell survival signalling by the ERK1/2 pathway.;K Balmanno;Cell Death Differ,2009

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities;Molecular Cancer;2023-12-18

2. The importance of Ras in drug resistance in cancer;British Journal of Pharmacology;2021-04-06

3. Anti-Proliferative, Pro-Apoptotic, Anti-Migrative and Tumor-Inhibitory Effects and Pleiotropic Mechanism of Theaflavin on B16F10 Melanoma Cells;OncoTargets and Therapy;2021-02

4. Investigation of novel sorafenib tosylate loaded biomaterial based nano-cochleates dispersion system for treatment of hepatocellular carcinoma;Journal of Dispersion Science and Technology;2021-02-01

5. Cell lines of human melanoma and their xenograft with braf or nras mutations a targets for targeted therapy. Reviews;Russian Journal of Biotherapy;2019-01-11